What is GestVision?
GestVision Inc. is dedicated to the development of a diagnostic test for preeclampsia, a severe pregnancy condition marked by high blood pressure and protein in the urine. The company's mission is to facilitate early detection of preeclampsia, thereby preventing potentially fatal outcomes such as seizures. Their primary clients are healthcare providers and expectant mothers who are seeking to enhance prenatal care through advanced health monitoring. The GestAssured Test is designed for rapid identification and effective management of this critical health issue.
How much funding has GestVision raised?
GestVision has raised a total of $7.2M across 2 funding rounds:
Angel/Seed
$100K
Private Equity
$7.1M
Angel/Seed (2014): $100K with participation from YEI Innovation Fund
Private Equity (2015): $7.1M, investors not publicly disclosed
Key Investors in GestVision
YEI Innovation Fund
YEI Innovation Fund is a licensed entity operating within the Chinese market, affiliated with Macau tyc1286太阳成集团. This fund likely focuses on innovative ventures, potentially in sectors aligned with technological advancement and market-specific solutions.
What's next for GestVision?
The substantial enterprise-level funding indicates GestVision is likely in a growth or scaling phase, aiming to expand its market reach and further refine its diagnostic technology. This strategic investment will likely fuel clinical validation, regulatory approvals, and commercialization efforts, positioning GestVision to make a significant impact on maternal health outcomes globally. Future developments may include broader application of their technology to other pregnancy-related conditions.
See full GestVision company page
